amicus
therapeutics
announces
additional
positive
interim
clinical
data
batten
disease
gene
therapy
annual
meeting
child
neurology
society
cranbury
globe
newswire
amicus
therapeutics
nasdaq
fold
today
announced
additional
positive
interim
results
batten
disease
gene
therapy
program
results
featured
virtual
poster
presentation
joint
international
child
neurology
congress
annual
child
neurology
society
meeting
held
october
presentation
also
available
events
presentations
section
amicus
therapeutics
corporate
website
http
abigail
wexner
research
institute
awri
nationwide
children
hospital
conducting
ongoing
phase
clinical
study
single
intrathecal
administration
gene
therapy
variant
neuronal
ceroid
lipofuscinosis
disease
also
known
batten
disease
approved
treatments
batten
disease
fatal
neurologic
disease
rapidly
robs
children
ability
walk
speak
think
see
clinical
data
highlights
interim
safety
data
available
children
batten
disease
interim
efficacy
data
available
first
children
reaching
timepoint
eight
children
months
gene
therapy
safety
treatment
generally
well
tolerated
majority
adverse
events
aes
mild
unrelated
treatment
pattern
adverse
events
related
aav
immunogenicity
observed
additional
details
provided
presentation
treatment
generally
well
tolerated
majority
adverse
events
aes
mild
unrelated
treatment
pattern
adverse
events
related
aav
immunogenicity
observed
additional
details
provided
presentation
hamburg
motor
language
aggregate
score
hamburg
motor
language
score
assessment
ambulation
speech
shows
meaningful
effect
slowing
disease
progression
months
combined
scale
mean
rate
decline
vs
points
months
treated
patients
vs
subjects
natural
history
cohort
combined
scale
mean
rate
decline
vs
points
months
treated
patients
vs
subjects
natural
history
cohort
hamburg
motor
language
score
assessment
ambulation
speech
shows
meaningful
effect
slowing
disease
progression
months
natural
history
within
natural
history
cohort
two
years
first
decline
hamburg
motor
language
score
subjects
experienced
additional
decline
compared
treated
patients
jeff
castelli
chief
development
officer
amicus
therapeutics
stated
pleased
share
positive
interim
clinical
data
intrathecal
aav
gene
therapy
community
data
continues
suggest
gene
therapy
potential
treatment
option
children
living
batten
disease
debilitating
condition
leads
progressive
declines
cognitive
motor
function
often
results
death
early
emily
de
los
reyes
principal
investigator
clinical
trial
awri
nationwide
children
professor
clinical
pediatrics
neurology
ohio
state
university
college
medicine
stated
remain
pleased
progress
trial
well
collection
natural
history
data
inform
results
gene
therapy
interim
results
show
investigational
gene
therapy
potential
slow
neurological
disease
progression
children
batten
regulatory
interactions
ongoing
company
expects
provide
feedback
path
forward
amicus
exclusive
rights
gene
therapy
program
developed
abigail
wexner
research
institute
nationwide
children
hospital
novel
gene
therapy
phase
development
batten
disease
rare
fatal
inherited
lysosomal
disorder
approved
treatment
primarily
affects
nervous
system
dosed
intrathecal
infusion
deliver
functional
copy
gene
cells
central
nervous
system
therapy
designed
address
underlying
enzyme
deficiency
results
progressive
cell
damage
neurodevelopmental
physical
decline
granted
rare
pediatric
disease
orphan
drug
designations
united
states
food
drug
administration
eu
company
holds
prime
orphan
medicinal
product
designations
batten
disease
batten
disease
common
name
broad
class
rare
fatal
inherited
disorders
nervous
system
also
known
neuronal
ceroid
lipofuscinoses
ncls
disorders
defect
specific
gene
triggers
cascade
problems
interferes
cell
ability
recycle
certain
molecules
gene
called
cln
ceroid
lipofuscinosis
neuronal
given
different
number
designation
subtype
known
forms
batten
disease
often
referred
various
types
batten
disease
similar
features
symptoms
vary
severity
age
onset
forms
batten
disease
ncls
usually
begin
childhood
clinical
course
often
involves
progressive
loss
independent
adaptive
skills
mobility
feeding
communication
patients
may
also
experience
vision
loss
personality
changes
behavioral
problems
learning
impairment
seizures
patients
typically
experience
progressive
loss
motor
function
eventually
become
bedridden
die
prematurely
amicus
therapeutics
amicus
therapeutics
nasdaq
fold
global
biotechnology
company
focused
discovering
developing
delivering
novel
medicines
people
living
rare
metabolic
diseases
extraordinary
patient
focus
amicus
therapeutics
committed
advancing
expanding
robust
pipeline
medicines
rare
metabolic
diseases
information
please
visit
company
website
follow
twitter
linkedin
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
relating
preclinical
clinical
development
product
candidates
timing
reporting
results
preclinical
studies
clinical
trials
prospects
timing
potential
regulatory
approval
product
candidates
particular
press
release
relates
interim
data
ongoing
phase
study
investigate
intrathecal
administration
gene
therapy
inclusion
statements
arising
interim
data
ongoing
study
natural
history
preliminary
data
regarded
representation
us
plans
achieved
statements
press
release
may
turn
wrong
affected
inaccurate
assumptions
might
make
known
unknown
risks
uncertainties
example
respect
statements
regarding
goals
progress
timing
outcomes
discussions
regulatory
authorities
particular
potential
goals
progress
timing
results
preclinical
studies
clinical
trials
actual
results
may
differ
materially
set
forth
release
due
risks
uncertainties
inherent
business
including
without
limitation
potential
results
clinical
preclinical
studies
indicate
product
candidates
unsafe
ineffective
potential
may
difficult
enroll
patients
clinical
trials
potential
regulatory
authorities
including
fda
ema
pmda
may
grant
may
delay
approval
product
candidates
potential
preclinical
clinical
studies
could
delayed
identify
serious
side
effects
safety
issues
potential
need
additional
funding
complete
studies
results
earlier
preclinical
studies
clinical
trials
may
predictive
future
results
interim
data
phase
study
discussed
herein
inherently
preliminary
early
study
derived
limited
patient
set
later
trial
results
patient
set
others
may
consistent
preliminary
results
addition
statements
subject
risks
detailed
annual
report
form
year
ended
december
quarterly
report
form
quarter
ended
june
cautioned
place
undue
reliance
statements
speak
date
hereof
statements
qualified
entirety
cautionary
statement
undertake
obligation
revise
update
news
release
reflect
events
circumstances
date
hereof
contacts
investors
amicus
therapeutics
andrew
faughnan
director
investor
relations
afaughnan
media
amicus
therapeutics
diana
moore
head
global
corporate
communications
dmoore
